Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
基本信息
- 批准号:10655435
- 负责人:
- 金额:$ 50.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AllelesAnti-Inflammatory AgentsApoptosisArthritisAtopic DermatitisAutophagocytosisBiochemicalBiological AssayBiological ProcessCell LineChildClinicalComplexCytokine SignalingDataDermatitisDevelopmentDiseaseEctopic ExpressionEvaluationFamilyFunctional disorderGastrointestinal tract structureGenesGenetic Predisposition to DiseaseGenetic VariationGoalsHealthHereditary DiseaseHumanHuman PathologyIL6ST geneIRF3 geneISG15 geneImmuneImmune System DiseasesImmune systemImmunityImmunologic ReceptorsImmunologicsImpairmentIn VitroIndividualInflammationInflammatoryIntellectual impairmentInterferon Type IInterferonsInterleukin-10Interleukin-6JAK1 geneKnowledgeLaboratoriesLesionMediatingMedicineMembranous GlomerulonephritisMethodsMolecularMutationNatural ImmunityNeurologicOutcomePathogenesisPathway interactionsPatientsPhenocopyPhenotypePhosphorylationPlayPoint MutationPredispositionProductionRIPK1 geneRegulationReportingRoleSTAT2 geneSeriesSignal PathwaySignal TransductionSkinSyndromeTBK1 geneTLR3 geneTNF geneTechnologyTherapeuticTransactivationUp-RegulationViralVirus Diseasesautoinflammationautoinflammatoryautoinflammatory diseasesbody systemcell typeclinically significantcytokinedesigndominant genetic mutationearly onsetenteritisexome sequencinggain of function mutationgastrointestinalgene functiongene producthuman diseaseimmunoregulationimprovedin vivoinnate immune functioninsightloss of function mutationmembernegative affectnovelpathogenprotein functionrecruitresponsetransmission processtype I interferon receptorwhite matter
项目摘要
Project Summary
Albeit rare, monogenic causes of complex disorders provide unique opportunities for a deeper
understanding of common diseases. In this application, we seek to study the molecular pathogenesis of novel,
rare, monogenic autoinflammatory disorders. Central clinical presentations of these syndromic patients include
severe skin inflammation, non-specific gastrointestinal inflammation, and aberrant neurologic features.
Using whole exome sequencing (WES) we have identified fourteen novel, exceedingly rare, inborn
genetic variations in genes with primary functions in innate immunity, specifically cytokine production,
transduction or regulation. These inborn errors of immunity are putative molecular drivers of autoinflammation,
the mechanisms of which we propose to explore in detail.
Type I Interferons (IFNs) are cytokines that signal through the JAK-STAT pathway. Beneficial effects of
IFNs largely concern antiviral defense, but profound detrimental effects to human health can manifest if this
pathway is overactive. Mendelian type I Interferonopathy disorders best exemplify how constitutive
upregulation of IFN-I activity can lead to aberrant immune and neurologic features.
We have recently identified and reported children presenting type I Interferonopathy features due to
complete loss-of-function mutations in either ISG15 or USP18, which are essential for shutting off the IFN-I
response at the IFN-I receptor. These deficiencies are the first genetic defects affecting the negative regulation
of the IFN-I response. In this proposal we seek to characterize patients with novel, complete or hypomorphic,
mutations in these two genes, but also patients who present with alike syndromes with mutations in genes that
either induce IFN-I or convey the signal downstream of IFN-I and other JAK-STAT engaging cytokines.
We propose to study these rare patients in vitro, ex vivo, and in vivo to determine the molecular,
immunological, and clinical significance of these genes in JAK-STAT pathway regulation, and, by extension,
their function in severe autoinflammatory immune regulation.
A deeper understanding of the molecular pathophysiology governing these disorders will lay the
groundwork for the development of medicines to better manage persistent inflammatory disorders, rare or
common.
项目摘要
虽然罕见,但复杂疾病的单基因病因为更深层次的
对常见病的了解。在这一应用中,我们试图研究新颖的、
罕见的单基因自体炎症性疾病。这些综合征患者的主要临床表现包括
严重的皮肤炎症,非特异性胃肠道炎症和异常的神经学特征。
利用整个外显子组测序(WES),我们已经鉴定了14个天生的、极其罕见的新
先天免疫主要功能基因的遗传变异,特别是细胞因子的产生,
转导或调节。这些与生俱来的免疫缺陷可能是自体炎症的分子驱动因素,
我们建议详细探讨其作用机制。
I型干扰素(IFN)是通过JAK-STAT途径传递信号的细胞因子。的有益影响
IFN主要涉及抗病毒防御,但如果这样做,可能会对人类健康产生深远的有害影响
通路过度活跃。孟德尔I型干扰素病最好的例证是如何构成
干扰素-I活性上调可导致免疫和神经功能异常。
我们最近发现并报告了出现I型干扰素病特征的儿童,原因是
ISG15或USP18中的完全功能丧失突变,这是切断干扰素-I所必需的
干扰素-I受体的反应。这些缺陷是影响负调控的第一个基因缺陷
干扰素-I的反应。在这项建议中,我们试图描述患者的特征为新奇的、完全的或亚形性的,
这两个基因的突变,以及出现类似综合征的患者的基因突变
诱导干扰素-I或将信号传递到干扰素-I和其他JAK-STAT参与细胞因子的下游。
我们建议在体外、体外和体内对这些罕见的患者进行研究,以确定分子,
这些基因在JAK-STAT通路调节中的免疫学和临床意义,进而,
它们在严重的自体炎症免疫调节中的作用。
对这些疾病的分子病理生理学有更深入的了解将为
为更好地管理罕见或持续性炎症性疾病的药物开发奠定基础
很普通。
项目成果
期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Individuals with JAK1 variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis.
携带 JAK1 变异的个体会受到自身免疫、特应性、结肠炎和皮炎等综合征特征的影响。
- DOI:10.1084/jem.20232387
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Horesh,MichaelE;Martin-Fernandez,Marta;Gruber,Conor;Buta,Sofija;LeVoyer,Tom;Puzenat,Eve;Lesmana,Harry;Wu,Yiming;Richardson,Ashley;Stein,David;Hodeib,Stephanie;Youssef,Mariam;Kurowski,JacobA;Feuille,Elizabeth;Pedroza,LuisA;
- 通讯作者:
ISG15 protects human Tregs from interferon alpha-induced contraction in a cell-intrinsic fashion.
- DOI:10.1002/cti2.1221
- 发表时间:2020
- 期刊:
- 影响因子:5.8
- 作者:Pacella I;Spinelli FR;Severa M;Timperi E;Tucci G;Zagaglioni M;Ceccarelli F;Rizzo F;Coccia EM;Patel RS;Martin-Fernandez M;Bogunovic D;Conti F;Barnaba V;Piconese S
- 通讯作者:Piconese S
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C).
- DOI:10.1101/2020.07.04.20142752
- 发表时间:2020-11-12
- 期刊:
- 影响因子:64.5
- 作者:Gruber, Conor N;Patel, Roosheel S;Bogunovic, Dusan
- 通讯作者:Bogunovic, Dusan
Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome.
I型干扰素的过度负调控会破坏唐氏综合症个体的病毒控制。
- DOI:10.1016/j.immuni.2022.09.007
- 发表时间:2022-11-08
- 期刊:
- 影响因子:32.4
- 作者:Malle, Louise;Martin-Fernandez, Marta;Buta, Sofija;Richardson, Ashley;Bush, Douglas;Bogunovic, Dusan
- 通讯作者:Bogunovic, Dusan
A partial form of inherited human USP18 deficiency underlies infection and inflammation.
- DOI:10.1084/jem.20211273
- 发表时间:2022-04-04
- 期刊:
- 影响因子:0
- 作者:Martin-Fernandez M;Buta S;Le Voyer T;Li Z;Dynesen LT;Vuillier F;Franklin L;Ailal F;Muglia Amancio A;Malle L;Gruber C;Benhsaien I;Altman J;Taft J;Deswarte C;Roynard M;Nieto-Patlan A;Moriya K;Rosain J;Boddaert N;Bousfiha A;Crow YJ;Jankovic D;Sher A;Casanova JL;Pellegrini S;Bustamante J;Bogunovic D
- 通讯作者:Bogunovic D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dusan Bogunovic其他文献
Dusan Bogunovic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dusan Bogunovic', 18)}}的其他基金
New York Regional Inborn Errors of Immunity Resource Initiative League (NY-ROYAL)
纽约地区先天性缺陷免疫资源倡议联盟 (NY-ROYAL)
- 批准号:
10554965 - 财政年份:2023
- 资助金额:
$ 50.23万 - 项目类别:
Immunologic and Predictive Features of MIS-C
MIS-C 的免疫学和预测特征
- 批准号:
10667530 - 财政年份:2022
- 资助金额:
$ 50.23万 - 项目类别:
Transient Gene Therapy as Broad Spectrum Antiviral
瞬时基因疗法作为广谱抗病毒药物
- 批准号:
10324302 - 财政年份:2021
- 资助金额:
$ 50.23万 - 项目类别:
Role of SARS-CoV-2-mediated Type I IFN antagonism in individuals with Down Syndrome
SARS-CoV-2 介导的 I 型 IFN 拮抗作用在唐氏综合症患者中的作用
- 批准号:
10158984 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10206016 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10120982 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10058607 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Inborn Errors of Immunity Leading to Autoinflammatory Syndromes
先天性免疫缺陷导致自身炎症综合征
- 批准号:
10443794 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10461962 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
Next Generation Resolution of Antiviral Gene Networks
抗病毒基因网络的下一代解决方案
- 批准号:
10681411 - 财政年份:2020
- 资助金额:
$ 50.23万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 50.23万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 50.23万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 50.23万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 50.23万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 50.23万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 50.23万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 50.23万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 50.23万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 50.23万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 50.23万 - 项目类别:














{{item.name}}会员




